Da effekten kan være reduceret, eller hyppigheden af overfølsomhed eller infusionsrelaterede reaktioner kan være forøget hos en patient med persisterende antistoffer, bør behandlingen afbrydes hos patienter, der udvikler persisterende antistoffer.
Given that efficacy may be reduced or the incidence of hypersensitivity or infusion-related reactions may be increased in a patient with persistent antibodies, treatment should be discontinued in patients who develop persistent antibodies.